PLSE at a glance
PULSE BIOSCIENCES, INC. (PLSE, SEC CIK 1625101) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 15, 2026 and Form 4 insider filings as recently as September 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), PULSE BIOSCIENCES, INC. (PLSE) reported revenue of $350,000 and a net loss of $72.8 million. Diluted EPS was -$1.08.
- As of June 30, 2026, 24 institutional investment managers tracked by SignalX reported holding PULSE BIOSCIENCES, INC. (PLSE) shares worth $175.2 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Teplitsky Liane Rae on September 1, 2026 of 1,001 shares at $49.95 per share.
- In the last 90 days, PLSE insiders reported 4 open-market purchases ($200K) and 0 open-market sales ($0) on Form 4, a net purchase of $200K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $350K
- 10-K XBRL
- Insiders · 90 days
- 4 buys · 0 sells
- Net +$200K
- 13F holders
- 24 funds
- $175.2M · +5 vs prior quarter
- Latest 8-K
- Sep 15, 2026
- Item 1.02 · Item 1.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue, margins, profitability, cash flow, and segment performance figures absent from provided excerpt
- February 2026 ATM: $46.8M net proceeds from 1,919,821 shares issued
- Capital allocation shifted toward electrophysiology, reducing cardiac surgery and Vybrance sales investments
- Cardiac catheter pivotal study: more than half of at least 164 evaluable patients enrolled
- Near-term headwinds: FDA PMA approval required before U.S. cardiac commercialization and continued financing needs
Risk Factors
- Additional capital needs, intensified by Middle East and Ukraine conflicts and rising tariffs, may force scaled-back operations
- Vybrance System adoption remains slow among surgeons, citing reimbursement uncertainty and limited long-term clinical data
- FDA changes and trade tariffs may increase operating costs and delay regulatory timelines
- Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic possess greater resources and established customer relationships
- Revenue dependence on the nPulse System and NPS platform concentrates commercial and product-development risk
AI summary of the PLSE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.02: Termination of a Material Definitive Agreement
- ATM offering program terminated September 14, 2026 under the February 19, 2026 TD Cowen Distribution Agreement
- Up to $1.0 million of remaining share capacity went unused at termination
Item 1.01: Entry into a Material Definitive Agreement
- New at-the-market facility authorizes up to $85 million in common-stock sales through Mizuho
- Company retains discretion to sell shares, creating potential funding flexibility without an immediate issuance commitment
Item 8.01: Other Events
- PRECISE-BTN enrollment completed at 100 patients, doubled from the original 50-patient design
- All patients enrolled across three U.S. clinical sites within approximately 12 months
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial and operational results announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the substantive results
AI summaries of PLSE 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PLSE
Don't miss the next PLSE filing
- Alerts as it files. A push when PLSE files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PLSE, by share count.
- Ask anything. An AI agent that reads every PLSE filing and answers with sources.
PLSE alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Teplitsky Liane Rae | Buy | Sep 1, 2026 | 1,001 | $49.95 |
| Teplitsky Liane Rae | Buy | Aug 31, 2026 | 1,024 | $48.80 |
| Teplitsky Liane Rae | Buy | Aug 28, 2026 | 1,034 | $48.35 |
| Teplitsky Liane Rae | Buy | Aug 26, 2026 | 1,036 | $48.23 |
| Teplitsky Liane Rae | A | Aug 8, 2026 | 700,000 | - |
| Teplitsky Liane Rae | A | Aug 8, 2026 | 200,000 | - |
| Zanganeh Mahkam | A | Jun 11, 2026 | 30,000 | - |
| Sainz Maria | A | Jun 11, 2026 | 3,793 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $0 | $350K |
| Operating Income | - | -$56.3M | -$76.9M |
| Net Income | -$42.2M | -$53.6M | -$72.8M |
| Op. Margin | - | - | -21982.6% |
| Net Margin | - | - | -20794.6% |
| Balance Sheet | |||
| Total Assets | $59.2M | $132.5M | $94.5M |
| Equity | - | $114.9M | $80.7M |
| ROE | - | -46.7% | -90.2% |
| Per Share | |||
| EPS | $-0.88 | $-0.92 | $-1.08 |
| Cash Flow | |||
| Operating CF | - | -$36.3M | -$54.1M |
| CapEx | $121K | $125K | $315K |
Source: XBRL data in PULSE BIOSCIENCES, INC. (PLSE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate PLSE share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 24 | $175.2M |
| Q1 2026 | 19 | $91.3M |
| Q4 2025 | 15 | $56.7M |
| Q3 2025 | 17 | $72.0M |
| Q2 2025 | 18 | $63.9M |
| Q1 2025 | 17 | $43.3M |
| Q4 2024 | 11 | $38.3M |
| Q3 2024 | 12 | $16.1M |
- T. Rowe Price Group+733.8K (+4938%)
- Bank of America Corp+580.5K (+67%)
- Citadel Advisors LLC+484.4K (+341%)
- BlackRock+126.9K (+9%)
- State Street Corp+72.7K (+16%)
- Millennium Management−32.3K (-58%)
- Vanguard Capital Management LLC−27.2K (-3%)
- Northern Trust−13.7K (-7%)
- Morgan Stanley−11.2K (-26%)
- PNC Financial Services−4.2K (-75%)
- Mangrove Partners+30.6K
- Raymond James Financial+15.3K
- Invesco Ltd+10.3K
- AQR Capital Management+8.6K
- U.S. Bancorp+2.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 133 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PLSE filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 15, 2026 | - | Analysis | - |
| 8-K | Sep 15, 2026 | - | Analysis | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 10-Q | May 14, 2026 | Mar 31, 2026 | Analysis | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 8-K | May 6, 2026 | - | Analysis | |
| 8-K | May 4, 2026 | - | Analysis | - |
| 8-K | Apr 27, 2026 | - | Analysis | - |
| 8-K | Apr 16, 2026 | - | Analysis | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
PLSE SEC filings: frequently asked questions
Are PLSE insiders buying or selling?
In the last 90 days, PULSE BIOSCIENCES, INC. (PLSE) officers, directors and 10% owners reported 4 open-market purchases worth $199,937 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold PLSE stock?
As of June 30, 2026, the largest PULSE BIOSCIENCES, INC. (PLSE) holders among the 13F filers tracked by SignalX were BlackRock ($40.7 million), Bank of America Corp ($40.1 million), Vanguard Capital Management LLC ($21.9 million), T. Rowe Price Group ($20.8 million), Citadel Advisors LLC ($17.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PLSE's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), PULSE BIOSCIENCES, INC. (PLSE) reported revenue of $350,000 and a net loss of $72.8 million. Diluted EPS was -$1.08. The figures come from the XBRL data in the 10-K.
What did PLSE report in its latest 8-K?
PULSE BIOSCIENCES, INC. (PLSE) filed an 8-K on September 15, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement) and Item 1.01 (Entry into a Material Definitive Agreement). ATM offering program terminated September 14, 2026 under the February 19, 2026 TD Cowen Distribution Agreement.
What are the latest PLSE SEC filings?
PULSE BIOSCIENCES, INC. (PLSE) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 15, 2026 and a Form 4 insider filing on September 2, 2026.
What is PLSE's SEC CIK number?
PULSE BIOSCIENCES, INC. (PLSE)'s SEC Central Index Key (CIK) is 1625101. EDGAR lists every PLSE filing under that number.
Ask anything about PLSE
The research agent reads PLSE's filings, financials, insider trades and 13F holders, then answers with sources.